ABPI Research shows Significant Promise for Stratified Medicines Impact on the UK Health System
Research by the ABPI shows that 90% of clinicians and other health professionals surveyed believe that stratified medicine — particularly non-cancer applications — will have a positive impact on the health system in the UK.
61% of the 300 health professionals polled by Concentra Consulting reported a ‘high interest’ in emerging uses of non-cancer stratified medicines whilst just 25% reported good access to non-cancer stratified medicines in their area currently.
The research report, Stratified medicine in the NHS: An assessment of the current landscape and implementation challenges for non-cancer applications also shows that 40% of respondents feel that the NHS is currently achieving little or no benefit from non-cancer stratified medicine but that almost a third (32%) believe it gives patients access to treatments they otherwise would not have had– highlighting the significant opportunities and challenges of stratified medicine in the UK.
Bina Rawal, ABPI’s Research, Medical and Innovation Director said: “Stratified medicine has real potential to change the way we identify and manage health problems and we have an exceptional opportunity in the UK to realise the benefits of stratified medicines for patients and the health service.
“Already significant progress has been made in the treatment of a number of cancers and this report highlights the number of non-cancer applications already in use in the NHS and the increasing interest and enthusiasm amongst health professionals of further adopting their use.”
The report, supported by the Royal College of Pathologists and launched at the ABPI’s annual R&D conference tomorrow, shows that there are currently 41 applications for non-cancer stratified medicines, of which there is variable knowledge and use across the NHS. The largest number of applications highlighted in this report were for infection, followed by respiratory and cardiovascular disease.
Clinicians and health professionals unanimously agreed (98%) that there are significant challenges to implementing stratified medicine in the NHS; with 90% claiming that the health system will need to change to support the adoption of stratified medicine.
Stratified medicine in the NHS: An assessment of the current landscape and implementation challenges for non-cancer applications includes six recommendations from the ABPI on reducing challenges and exploiting opportunities in stratified medicines from horizon scanning through commissioning to provision and decision making.
Bina Rawal said: “Although overall progress in stratified medicine has perhaps been slower than hoped, it represents important steps towards realising the significant benefits to patients, prescribers and healthcare payers of a stratified medicine approach.
“This research report, our previous papers on stratified medicine and our focus at this year’s R&D conference on the challenge and opportunity of stratified medicine signals the pharmaceutical industry’s commitment to embedding stratified medicines to ensure that the right patient receives the right medicine at the right time.”
Professor Ian Cree, Chair of the Interspeciality Committee on Molecular Pathology, Royal College of Pathologists added: “We know that there is currently a significant lack of clarity around which non-cancer application stratified medicines are being researched and developed and how they are being deployed in the NHS. This report provides a baseline understanding from which we can start to seek solutions for balancing the ecosystem to create a health system that will allow stratified medicines to flourish in the UK for the benefit of patients.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance